| HOME >> BIOLOGY >> TECHNOLOGY |
Aliso Viego, CA (PRWEB) March 11, 2013
Histogen Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, has partnered with a Southern California medical device executive management and investment group to establish PUR Biologics, LLC. PUR is a joint venture focused on the emerging field of biologics for musculoskeletal conditions, including spine, dental and medical device applications.
Under this joint venture, PUR Biologics has acquired exclusive worldwide rights to Histogen’s human multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials for use in the orthopedic areas of bone, cartilage, spinal disc and ligament regeneration, as well as device coatings. A soluble composition of naturally-secreted proteins, the CCM contains growth factors such as follistatin and stem cell factor which are known to stimulate stem cell growth, differentiation, and tissue regeneration. The insoluble ECM, made up of a variety of collagens and other matrix proteins, holds promise as an excellent biologically-active filler, attracting fibroblasts and stem cells as well as supporting new tissue growth.
“Regenerative technologies are paramount in advancing the current state or orthopedics and neurosurgery,” said Dr. Chad Prusmack Chief of Neurosurgery at Rocky Mountain Spine Clinic and consultant to the Denver Broncos. “The use of naturally-secreted human growth factors and matrix proteins, known to stimulate and support stem cell growth in the body, can prove to be transformational in the regeneration of multiple musculoskeletal and neuronal tissues .These unique preparations may be the universal 'transducer' needed for optimizing directed stem cell differentiation and healthy proliferation."
PUR Biologics will build upon early proof-of-concept data to bring orthopedic products based on the CCM and ECM through a
'/>"/>
| Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved |
Related biology technology :
1. Harvards Wyss Institute creates living human gut-on-a-chip
2. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
3. Plasma startup creates high-energy light to make smaller microchips
4. UMD creates new tech for complex micro structures for use in sensors & other apps
5. Harvards Wyss Institute team creates versatile 3d nanostructures using DNA bricks
6. Fitting smart mobile phone with magnifying optics creates real cell phone
7. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
9. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. Adeona Becomes Synthetic Biologics, Inc.
11. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |